Licensing and Access to Medicines

Our expert panel identifies and discusses the barriers to non-exclusive licensing and other forms of public return on public investment by public research organisations and their impact on access to health technologies. In doing so, they consider the current pandemic context, ongoing discussions, and future health emergencies.